Prognostic Impact of Familial Screening in Dilated Cardiomyopathy
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Aims: Familial screening of patients with dilated cardiomyopathy (DCM) allows an early diagnosis of the disease in family members. It is unclear if familial forms (FDC) have a different long-term outcome compared with sporadic DCM. Our aim was to compare the long-term prognosis of FDC and sporadic forms in order to assess the role of familial screening. Methods and results: Between 1988 and 2007, 637 DCM patients were consecutively enrolled. Of these, 130 patients (20.4%) had FDC, including 82 (12.9%) probands and 48 (7.5%) non-proband FDC patients (NP-FDC), identified by family screening. We compared the 48 NP-FDC patients with a sample of 96 patients with sporadic DCM, who were randomly matched by year of enrolment in a 2:1 ratio. At enrolment the NP-FDC patients were younger (40 ± 16 vs. 48 ± 13 years, P = 0.002), less symptomatic [New York Heart Association, (NYHA) III–IV: 8 vs. 28%, P = 0.006], had higher left ventricular ejection fraction (35 ± 10 vs. 30 ± 9%, P = 0.005) and were less intensively treated with evidence-based drugs than the sporadic DCM patients. Survival free from heart transplant at 2, 5 and 10 years was 93, 91 and 82%, respectively, in NP-FDC patients compared with 86, 76 and 62% in sporadic forms (P = 0.04). After stratification for NYHA classes, no difference in survival was observed between sporadic and NP-FDC patients. Conclusion: Our study demonstrates that family screening can effectively identify DCM patients at an earlier stage of disease and can improve survival. The possibility of changing the prognosis of DCM needs to be verified in patients intensively treated with tailored medical treatment. Family screening should be recommended for all DCM patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure
Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., Domanski, M., Troutman, C., Anderson, J., Johnson, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043399 · Cited by 6,552
(1996) · Circulation · doi:10.1161/01.cir.93.5.841 · Cited by 3,458 · cited 2×
“Dilated cardiomyopathy (DCM) is a heart muscle disease characterized by left ventricular dilatation and systolic dysfunction in the absence of abnormal loading conditions or coronary artery disease sufficient to cause the observed impairment.(1,2) It is an important factor in mortality and morbidity, as well as a freq…”
BackgroundMethodNatural history of asymptomatic left ventricular systolic dysfunction in the community
Wang, T. J., Evans, J. C., Benjamin, E. J., Levy, D., LeRoy, E. C., & Vasan, R. S. (2003) · Circulation · doi:10.1161/01.cir.0000085166.44904.79 · Cited by 633
Cited by
Dilated Cardiomyopathy: Genetic Determinants and Mechanisms
McNally, E. M., & Mestroni, L. (2017) · Circulation Research · doi:10.1161/circresaha.116.309396 · Cited by 786
“earlier stages of disease, and this associates with improved survival as compared with sporadic DCM.(148)”
Self-citationGenetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice Guideline
Hershberger, R. E., Lindenfeld, J., Mestroni, L., Seidman, C. E., Taylor, M. R. G., & Towbin, J. A. (2009) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.01.006 · Cited by 702
Self-citationGenetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice Guideline
Hershberger, R. E., Givertz, M. M., Ho, C. Y., Judge, D. P., Kantor, P. F., McBride, K. L., Morales, A., Taylor, M. R. G., Vatta, M., & Ware, S. M. (2018) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2018.03.004 · Cited by 446
Evolving Concepts in Dilated Cardiomyopathy
Merlo, M., Cannatà, A., Gobbo, M., Stolfo, D., Elliott, P. M., & Sinagra, G. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1103 · Cited by 331
Self-citationMerlo, M., Pivetta, A., Pinamonti, B., Stolfo, D., Zecchin, M., Barbati, G., Di Lenarda, A., & Sinagra, G. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.16 · Cited by 220
“Heart transplant, n (%) 6 (6) 51 (14) 17 (5) 0.”
Self-citation
Metadata
- Authors
- Moretti, M., Merlo, M., Barbati, G., Di Lenarda, A., Brun, F., Pinamonti, B., Gregori, D., Mestroni, L., & Sinagra, G.
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-09-01
- Volume
- 12
- Issue
- 9
- Pages
- 922-927
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W2066544645
- Cited by
- 65
- References
- 3
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic Impact of Familial Screening in Dilated Cardiomyopathy. https://app.cochat.ai/papers/10.1093/eurjhf/hfq093
- The paper
- Moretti, M., Merlo, M., Barbati, G., Di Lenarda, A., Brun, F., Pinamonti, B., Gregori, D., Mestroni, L., & Sinagra, G. (2010). Prognostic Impact of Familial Screening in Dilated Cardiomyopathy. European Journal of Heart Failure. https://doi.org/10.1093/eurjhf/hfq093
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.